Also known as IMGN853 and Elahere.
Revenue +8.4% AER; core operating profit +11.2% AER; ORZEYFUL approved in US/Japan/China; MIMRYLO launched in US; zasocitinib accepted for FDA Priority Review; FY outlook raised for FX.
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
